OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is associated with abnormalities in basal glucose and free fatty acid (FFA) metabolism, multi-organ insulin resistance and alterations in lipoprotein kinetics. These metabolic outcomes can be evaluated in vivo by using stable isotopically labeled tracer methods. An understanding of the reproducibility of these measures is necessary to ensure adequate statistical power in studies designed to evaluate metabolic function in subjects with NAFLD. METHODS: We determined the degree of intra-individual variability of skeletal muscle, adipose tissue, and hepatic insulin sensitivity and basal plasma glucose, FFA, and very-low-density lipoprotein triglyceride and apolipoprotein B-100 (apoB-100) kinetics in eight obese subjects with NAFLD (age: 44 ± 3 years; body mass index: 38.2 ± 1.7 kg m(-2); intrahepatic triglyceride content: 24.5 ± 3.9%), by using the hyperinsulinemic-euglycemic clamp technique and stable isotope-labeled tracer methods and mathematical modeling on two separate occasions ∼2 months apart. RESULTS: The intra-individual variability (coefficient of variation) ranged from 6% for basal glucose production to 21% for insulin-stimulated glucose disposal (percentage increase from basal). We estimated that a 25% difference in any outcome measure can be detected with a sample size of ≤ 8 subjects for paired studies and ≤ 15 subjects per group for unpaired studies, assuming an α value of 0.05 and a β value of 0.20 (that is, 80% power). CONCLUSION: These results demonstrate that only a small number of subjects are needed to detect clinically relevant effects in insulin sensitivity and hepatic lipoprotein metabolism in obese subjects with NAFLD, and will be useful to determine appropriate sample size for future metabolic studies.
OBJECTIVE:Non-alcoholic fatty liver disease (NAFLD) is associated with abnormalities in basal glucose and free fatty acid (FFA) metabolism, multi-organ insulin resistance and alterations in lipoprotein kinetics. These metabolic outcomes can be evaluated in vivo by using stable isotopically labeled tracer methods. An understanding of the reproducibility of these measures is necessary to ensure adequate statistical power in studies designed to evaluate metabolic function in subjects with NAFLD. METHODS: We determined the degree of intra-individual variability of skeletal muscle, adipose tissue, and hepatic insulin sensitivity and basal plasma glucose, FFA, and very-low-density lipoprotein triglyceride and apolipoprotein B-100 (apoB-100) kinetics in eight obese subjects with NAFLD (age: 44 ± 3 years; body mass index: 38.2 ± 1.7 kg m(-2); intrahepatic triglyceride content: 24.5 ± 3.9%), by using the hyperinsulinemic-euglycemic clamp technique and stable isotope-labeled tracer methods and mathematical modeling on two separate occasions ∼2 months apart. RESULTS: The intra-individual variability (coefficient of variation) ranged from 6% for basal glucose production to 21% for insulin-stimulated glucose disposal (percentage increase from basal). We estimated that a 25% difference in any outcome measure can be detected with a sample size of ≤ 8 subjects for paired studies and ≤ 15 subjects per group for unpaired studies, assuming an α value of 0.05 and a β value of 0.20 (that is, 80% power). CONCLUSION: These results demonstrate that only a small number of subjects are needed to detect clinically relevant effects in insulin sensitivity and hepatic lipoprotein metabolism in obese subjects with NAFLD, and will be useful to determine appropriate sample size for future metabolic studies.
Authors: Elisa Fabbrini; B Selma Mohammed; Faidon Magkos; Kevin M Korenblat; Bruce W Patterson; Samuel Klein Journal: Gastroenterology Date: 2007-11-28 Impact factor: 22.682
Authors: Samuel Klein; Bettina Mittendorfer; J Christopher Eagon; Bruce Patterson; Lafaine Grant; Nikki Feirt; Ekihiro Seki; David Brenner; Kevin Korenblat; Jennifer McCrea Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein Journal: Proc Natl Acad Sci U S A Date: 2009-08-24 Impact factor: 11.205
Authors: Erik Kirk; Dominic N Reeds; Brian N Finck; S Mitra Mayurranjan; Mitra S Mayurranjan; Bruce W Patterson; Samuel Klein Journal: Gastroenterology Date: 2009-01-25 Impact factor: 22.682
Authors: Vera B Schrauwen-Hinderling; Marco Mensink; Matthijs K C Hesselink; Jean-Pierre Sels; M Eline Kooi; Patrick Schrauwen Journal: J Clin Endocrinol Metab Date: 2008-05-06 Impact factor: 5.958
Authors: Shelby Sullivan; Elisa Fabbrini; Jay D Horton; Kevin Korenblat; Bruce W Patterson; Samuel Klein Journal: Transl Res Date: 2011-07-19 Impact factor: 7.012
Authors: Faidon Magkos; Gemma Fraterrigo; Jun Yoshino; Courtney Luecking; Kyleigh Kirbach; Shannon C Kelly; Lisa de Las Fuentes; Songbing He; Adewole L Okunade; Bruce W Patterson; Samuel Klein Journal: Cell Metab Date: 2016-02-22 Impact factor: 27.287
Authors: Robert H Coker; Nicholas P Hays; Rick H Williams; Lulu Xu; Robert R Wolfe; William J Evans Journal: J Gerontol A Biol Sci Med Sci Date: 2013-07-31 Impact factor: 6.053
Authors: Elisa Fabbrini; Jun Yoshino; Mihoko Yoshino; Faidon Magkos; Courtney Tiemann Luecking; Dmitri Samovski; Gemma Fraterrigo; Adewole L Okunade; Bruce W Patterson; Samuel Klein Journal: J Clin Invest Date: 2015-01-02 Impact factor: 14.808
Authors: Xuewen Wang; Gordon I Smith; Bruce W Patterson; Dominic N Reeds; Janine Kampelman; Faidon Magkos; Bettina Mittendorfer Journal: Am J Physiol Endocrinol Metab Date: 2012-01-17 Impact factor: 4.310
Authors: Jun Yoshino; Paloma Almeda-Valdes; Bruce W Patterson; Adewole L Okunade; Shin-ichiro Imai; Bettina Mittendorfer; Samuel Klein Journal: J Clin Endocrinol Metab Date: 2014-05-30 Impact factor: 5.958
Authors: Gissette Reyes-Soffer; Byoung Moon; Antonio Hernandez-Ono; Marija Dionizovik-Dimanovski; Marija Dionizovick-Dimanovski; Jhonsua Jimenez; Joseph Obunike; Tiffany Thomas; Colleen Ngai; Nelson Fontanez; Daniel S Donovan; Wahida Karmally; Stephen Holleran; Rajasekhar Ramakrishnan; Robert S Mittleman; Henry N Ginsberg Journal: Sci Transl Med Date: 2016-01-27 Impact factor: 17.956